ReviewOncotarget2022

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations.

Antonio Marchetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.